Expand RARE Menu
RARE MENU

RARE Latest Press Releases

-- April 15, 2024 --

Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102 Globe Newswire 7:00 AM

-- April 12, 2024 --

Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome Globe Newswire 4:22 PM
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting Globe Newswire 8:00 AM

-- March 22, 2024 --

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM

-- February 27, 2024 --

Ultragenyx to Participate at Investor Conferences in March Globe Newswire 4:30 PM

-- February 23, 2024 --

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- February 15, 2024 --

Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update Globe Newswire 4:01 PM

-- February 8, 2024 --

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update Globe Newswire 4:00 PM

-- February 6, 2024 --

Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA) Globe Newswire 8:00 AM

-- February 5, 2024 --

Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome Globe Newswire 4:05 PM

-- January 25, 2024 --

Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease Globe Newswire 4:05 PM

-- January 19, 2024 --

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:00 PM

-- January 8, 2024 --

Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments Globe Newswire 7:00 AM

-- January 7, 2024 --

Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones Globe Newswire 11:00 AM

-- January 4, 2024 --

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza ? (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH) Globe Newswire 8:00 AM

-- January 3, 2024 --

Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome Globe Newswire 8:00 AM

-- January 2, 2024 --

Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference Globe Newswire 4:05 PM

-- December 21, 2023 --

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- December 18, 2023 --

Andelyn Biosciences Selected by Ultragenyx for Late-Stage Process Performance Qualification (PPQ) Manufacturing of Novel Gene Therapy for Sanfilippo Syndrome PRNewswire 9:29 AM
Ultragenyx Receives European Commission Decision for Evkeeza (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH) Globe Newswire 8:00 AM

-- November 20, 2023 --

Ultragenyx to Participate at Investor Conferences in November Globe Newswire 4:30 PM